158 related articles for article (PubMed ID: 26211902)
1. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
2. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
[TBL] [Abstract][Full Text] [Related]
3. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
4. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release.
Luan J; Zhang D; Hao L; Li C; Qi L; Guo H; Liu X; Zhang Q
Drug Deliv; 2013 Nov; 20(8):324-30. PubMed ID: 24032657
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
8. [Preparation and characterization of oxaliplatin-loaded nanostructured lipid carriers].
Zhou H; Qiu LP; Yan XX; Li L; Li X; Wang L; Liu M; Wang DK
Yao Xue Xue Bao; 2010 Sep; 45(9):1177-82. PubMed ID: 21351576
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
10. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
[TBL] [Abstract][Full Text] [Related]
11. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
Neupane YR; Srivastava M; Ahmad N; Kumar N; Bhatnagar A; Kohli K
Int J Pharm; 2014 Dec; 477(1-2):601-12. PubMed ID: 25445972
[TBL] [Abstract][Full Text] [Related]
12. Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers.
Wang Z; Wang J; Yang S; Hou S
Drug Dev Ind Pharm; 2016 Jan; 42(1):91-98. PubMed ID: 25853294
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of silybin-loaded nanostructured lipid carriers.
Jia LJ; Zhang DR; Li ZY; Feng FF; Wang YC; Dai WT; Duan CX; Zhang Q
Drug Deliv; 2010 Jan; 17(1):11-8. PubMed ID: 19941406
[TBL] [Abstract][Full Text] [Related]
14. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies.
Bondì ML; Craparo EF; Giammona G; Cervello M; Azzolina A; Diana P; Martorana A; Cirrincione G
Drug Deliv; 2007 Feb; 14(2):61-7. PubMed ID: 17364869
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characteristics of monostearin nanostructured lipid carriers.
Hu FQ; Jiang SP; Du YZ; Yuan H; Ye YQ; Zeng S
Int J Pharm; 2006 May; 314(1):83-9. PubMed ID: 16563671
[TBL] [Abstract][Full Text] [Related]
19. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]